Estrella Immunopharma Inc (ESLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,064 | -12,450 | -7,649 | -2,104 | -4,427 |
| Accounts payable and accrued liabilities | 550 | 1 | 4 | 10 | 4 |
| Other Working Capital | 10,621 | 10,305 | 6,450 | 1,479 | 881 |
| Other Operating Activity | 107 | 536 | 315 | 150 | 428 |
| Operating Cash Flow | $-1,786 | $-1,608 | $-881 | $-466 | $-3,114 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,400 | 2,400 | 1,350 | N/A | 80 |
| Common Stock Repurchased | -30 | -30 | -30 | -30 | -215 |
| Other Financing Activity | -117 | -53 | -40 | 0 | 0 |
| Financing Cash Flow | $2,253 | $2,318 | $1,281 | $-30 | $-135 |
| Beginning Cash Position | 917 | 917 | 917 | 917 | 4,165 |
| End Cash Position | 1,384 | 1,627 | 1,317 | 422 | 917 |
| Net Cash Flow | $467 | $710 | $400 | $-495 | $-3,249 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,786 | -1,608 | -881 | -466 | -3,114 |
| Free Cash Flow | -1,786 | -1,608 | -881 | -466 | -3,114 |